Ken O'Flynn

1013. Deputy Ken O'Flynn asked the Minister for Health the estimated annual expenditure associated with obesity-related prescribing, including diabetes, cardiovascular and weight-management medications, in each year since 2020. [36644/26]

1014. Deputy Ken O'Flynn asked the Minister for Health whether any assessment has been carried out regarding the projected impact of obesity-related disease on future acute hospital capacity demand and workforce requirements to 2035. [36645/26]

1015. Deputy Ken O'Flynn asked the Minister for Health whether obesity-related disease expenditure is separately identifiable within the HSE budgeting process; and if not, whether this has been identified as a strategic planning weakness. [36646/26]

1016. Deputy Ken O'Flynn asked the Minister for Health whether the Department has assessed the long-term economic impact of childhood obesity trends on future healthcare expenditure and labour-force participation. [36647/26]

1021. Deputy Ken O'Flynn asked the Minister for Health the total monetary value of rejected or unpaid pharmacy claims under the General Medical Services Scheme attributable to administrative or submission errors in each year from 2020 to 2026, in tabular form. [36741/26]

1022. Deputy Ken O'Flynn asked the Minister for Health the most common categories of administrative or submission errors resulting in rejected or unpaid pharmacy claims under the general medical services scheme in 2024 and 2025 [36742/26]

1023. Deputy Ken O'Flynn asked the Minister for Health the average time taken to resolve and reimburse corrected pharmacy claims originally rejected due to administrative or submission errors. [36743/26]

1024. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has conducted any assessment of the financial or operational impact of rejected pharmacy claims on independent community pharmacies. [36744/26]

1025. Deputy Ken O'Flynn asked the Minister for Health whether any national targets or key performance indicators exist to reduce the proportion of rejected or unpaid pharmacy claims attributable to administrative or submission errors. [36745/26]

1026. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has considered introducing additional automated pre-submission validation systems to reduce pharmacy claim rejection rates. [36746/26]

1027. Deputy Ken O'Flynn asked the Minister for Health the proportion of rejected pharmacy claims subsequently resubmitted successfully as corrected reclaims in each year from 2020 to 2026. [36747/26]

1028. Deputy Ken O'Flynn asked the Minister for Health whether any review has been undertaken into whether pharmacy software compatibility issues contribute disproportionately to rejected or unpaid claims. [36748/26]

1029. Deputy Ken O'Flynn asked the Minister for Health the financial impact on annual PCRS expenditure arising from the 2022 steri-neb salamol price uplift. [36753/26]

1030. Deputy Ken O'Flynn asked the Minister for Health the rationale and assessment process underpinning the 2022 reimbursement price uplift granted to Steri-neb Salamol 2.5mg/2.5ml. [36754/26]

1031. Deputy Ken O'Flynn asked the Minister for Health whether any cost-effectiveness, inflationary, supply-chain or market-availability assessment was undertaken prior to the Steri-neb Salamol price uplift. [36755/26]

1032. Deputy Ken O'Flynn asked the Minister for Health how many medicinal products received reimbursement price uplifts under PCRS arrangements in each year from 2020 to 2026. [36756/26]

1033. Deputy Ken O'Flynn asked the Minister for Health the estimated additional annual expenditure arising from reference pricing adjustments which increased reimbursement rates rather than reduced them. [36757/26]

1034. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE publishes any annual review of reimbursement price uplifts and their impact on medicines expenditure. [36758/26]

1035. Deputy Ken O'Flynn asked the Minister for Health whether pharmacies or representative bodies are formally consulted before reimbursement rule changes or reference pricing adjustments are introduced. [36759/26]

1036. Deputy Ken O'Flynn asked the Minister for Health the total expenditure by each individual hospital and hospital group on private ambulance services in each year from 2020 to date in 2026, in tabular form. [36778/26]

1037. Deputy Ken O'Flynn asked the Minister for Health whether any national procurement framework exists governing the engagement of private ambulance providers by HSE-funded hospitals. [36779/26]

1038. Deputy Ken O'Flynn asked the Minister for Health whether all private ambulance providers contracted by HSE-funded hospitals are required to meet specified national clinical governance and patient safety standards. [36780/26]

1039. Deputy Ken O'Flynn asked the Minister for Health whether her Department or the HSE maintains any register of private ambulance providers engaged by publicly funded hospitals. [36781/26]

1040. Deputy Ken O'Flynn asked the Minister for Health whether any assessment has been carried out regarding the impact of reliance on private ambulance services on continuity of care, patient safety, or response times. [36782/26]

1041. Deputy Ken O'Flynn asked the Minister for Health the number of additional National Ambulance Service intermediate care staff and vehicles projected to be required nationally to eliminate reliance on private ambulance providers. [36783/26]